Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer

Current Cancer Drug Targets

Volumn 8, Issue 7, 2008, Pages 597-610

  Lanzino, Marilena ^a   Morelli, Catia ^a   Garofalo, Cecilia ^a   Panno, Maria Luisa ^a   Mauro, Loredana ^a   Andò, Sebastiano ^a   Sisci, Diego ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Akt; EGFR; ErbB; Estrogen receptor; HER2 neu; IGF I; IGF IR; IRS 1; MNAR; PI3K; Shc

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ESTROGEN; ESTROGEN RECEPTOR ALPHA; GLUCOSE TRANSPORTER 4; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SH2; PROTEIN SHC; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR AP 1; UNINDEXED DRUG;

BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTROGEN RECEPTOR ALPHA; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; PROTEIN BINDING; SIGNAL TRANSDUCTION;

EID: 55449136933     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800908786241104     Document Type: Review

References (199)

1. Gustafsson, J. A. What pharmacologists can learn from recent advances in estrogen signalling. Trends Pharmacol. Sci. 2003, 24, 479-485.
2. Deroo, B. J.; Korach, K. S. Estrogen receptors and human disease. J. Clin. Invest. 2006, 116, 561-570.
3. Couse, J. F.; Korach, K. S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev. 1999, 20, 358-417.
4. Heldring, N.; Pike, A.; Andersson, S.; Matthews, J.; Cheng, G.; Hartman, J.; Tujague, M.; Strom, A.; Treuter, E.; Warner, M.; Gustafsson, J. A. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87, 905-931.
5. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83, 835-839.
6. Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93, 5925-5930.
7. Kuiper, G. G.; Carlsson, B.; Grandien, K.; Enmark, E.; Haggblad, J.; Nilsson, S.; Gustafsson, J. A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138, 863-870.
8. Cheskis, B. J.; Greger, J. G.; Nagpal, S.; Freedman, L. P. Signaling by estrogens. J. Cell Physiol. 2007, 213, 610-617.
9. Tsai, M. J.; O'Malley, B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63, 451-486.
10. Katzenellenbogen, J. A.; Katzenellenbogen, B. S. Nuclear hormone receptors: ligand-activated regulators of transcription and diverse cell responses. Chem. Biol. 1996, 3, 529-536.
11. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240, 889-895.
12. O'Connor, R.; Fennelly, C.; Krause, D. Regulation of survival signals from the insulin-like growth factor-I receptor. Biochem. Soc. Trans. 2000, 28, 47-51.
13. Berry, M.; Metzger, D.; Chambon, P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 1990, 9, 2811-2818.
14. Onate, S. A.; Boonyaratanakornkit, V.; Spencer, T. E.; Tsai, S. Y.; Tsai, M. J.; Edwards, D. P.; O'Malley, B. W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 1998, 273, 12101-12108.
15. McInerney, E. M.; Tsai, M. J.; O'Malley, B. W.; Katzenellenbogen, B. S. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. Proc. Natl. Acad. Sci. USA 1996, 93, 10069-10073.
16. Ing, N. H.; Beekman, J. M.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J. Biol. Chem. 1992, 267, 17617-17623.
17. Wahli, W.; Martinez, E. Superfamily of steroid nuclear receptors: positive and negative regulators of gene expression. FASEB J. 1991, 5, 2243-2249.
18. Freedman, L. P. Anatomy of the steroid receptor zinc finger region. Endocr. Rev. 1992, 13, 129-145.
19. Zilliacus, J.; Wright, A. P.; Carlstedt-Duke, J.; Gustafsson, J. A. Structural determinants of DNA-binding specificity by steroid receptors. Mol. Endocrinol. 1995, 9, 389-400.
20. Dahlman-Wright, K.; Wright, A.; Gustafsson, J. A.; Carlstedt-Duke, J. Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids. J. Biol. Chem. 1991, 266, 3107-3112.
21. Edwards, D. P. The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors. J. Mammary Gland Biol. Neoplasia 2000, 5, 307-324.
22. Adler, S.; Waterman, M. L.; He, X.; Rosenfeld, M. G. Steroid receptor-mediated inhibition of rat prolactin gene expression does not require the receptor DNA-binding domain. Cell 1988, 52, 685-695.
23. Giguere, V.; Yang, N.; Segui, P.; Evans, R. M. Identification of a new class of steroid hormone receptors. Nature 1988, 331, 91-94.
24. Montano, M. M.; Muller, V.; Trobaugh, A.; Katzenellenbogen, B. S. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol. Endocrinol. 1995, 9, 814-825.
25. Koide, A.; Zhao, C.; Naganuma, M.; Abrams, J.; Deighton-Collins, S.; Skafar, D. F.; Koide, S. Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions. Mol. Endocrinol. 2007, 21, 829-842.
26. Kuiper, G. G.; Lemmen, J. G.; Carlsson, B.; Corton, J. C.; Safe, S. H.; van der Saag, P. T.; van der Burg, B.; Gustafsson, J. A. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139, 4252-4263.
27. Barkhem, T.; Carlsson, B.; Nilsson, Y.; Enmark, E.; Gustafsson, J.; Nilsson, S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54, 105-112.
28. Pietras, R. J.; Arboleda, J.; Reese, D. M.; Wongvipat, N.; Pegram, M. D.; Ramos, L.; Gorman, C. M.; Parker, M. G.; Sliwkowski, M. X.; Slamon, D. J. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995, 10, 2435-2446.
29. Shupnik, M. A. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 2004, 23, 7979-7989.
30. Liegibel, U. M.; Sommer, U.; Boercsoek, I.; Hilscher, U.; Bierhaus, A.; Schweikert, H. U.; Nawroth, P.; Kasperk, C. Androgen receptor isoforms AR-A and AR-B display functional differences in cultured human bone cells and genital skin fibroblasts. Steroids 2003, 68, 1179-1187.
31. McKenna, N. J.; Lanz, R. B.; O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20, 321-344.
32. O'Malley, B. W. Coregulators: from whence came these "master genes". Mol. Endocrinol. 2007, 21, 1009-1013.
33. Dilworth, F. J.; Chambon, P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 2001, 20, 3047-3054.
34. Beekman, J. M.; Allan, G. F.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol. Endocrinol. 1993, 7, 1266-1274.
35. Kraus, W. L.; Kadonaga, J. T. p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev. 1998, 12, 331-342.
36. Shibata, H.; Spencer, T. E.; Onate, S. A.; Jenster, G.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog. Horm. Res. 1997, 52, 141-164; discussion 164-145.
37. O'Lone, R.; Frith, M. C.; Karlsson, E. K.; Hansen, U. Genomic targets of nuclear estrogen receptors. Mol. Endocrinol. 2004, 18, 1859-1875.
38. Metivier, R.; Penot, G.; Hubner, M. R.; Reid, G.; Brand, H.; Kos, M.; Gannon, F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115, 751-763.
39. Acconcia, F.; Kumar, R. Signaling regulation of genomic and non-genomic functions of estrogen receptors. Cancer Lett. 2006, 238, 1-14.
40. Bjornstrom, L.; Sjoberg, M. Mutations in the estrogen receptor DNA-binding domain discriminate between the classical mechanism of action and cross-talk with Stat5b and activating protein 1 (AP-1). J. Biol. Chem. 2002, 277, 48479-48483.
41. Gaub, M. P.; Bellard, M.; Scheuer, I.; Chambon, P.; Sassone-Corsi, P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990, 63, 1267-1276.
42. Kalaitzidis, D.; Gilmore, T. D. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol. Metab. 2005, 16, 46-52.
43. Sabbah, M.; Courilleau, D.; Mester, J.; Redeuilh, G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc. Natl. Acad. Sci. USA 1999, 96, 11217-11222.
44. Castro-Rivera, E.; Samudio, I.; Safe, S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J. Biol. Chem. 2001, 276, 30853-30861.
45. Altucci, L.; Addeo, R.; Cicatiello, L.; Dauvois, S.; Parker, M. G.; Truss, M.; Beato, M.; Sica, V.; Bresciani, F.; Weisz, A. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996, 12, 2315-2324.
46. Bjornstrom, L.; Sjoberg, M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 2005, 19, 833-842.
47. Prisco, M.; Santini, F.; Baffa, R.; Liu, M.; Drakas, R.; Wu, A.; Baserga, R. Nuclear translocation of insulin receptor substrate-1 by the simian virus 40 T antigen and the activated type 1 insulin-like growth factor receptor. J. Biol. Chem. 2002, 277, 32078-32085.
48. Norman, A. W.; Mizwicki, M. T.; Norman, D. P. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discov. 2004, 3, 27-41.
49. Levin, E. R. Integration of the extranuclear and nuclear actions of estrogen. Mol. Endocrinol. 2005, 19, 1951-1959.
50. Migliaccio, A.; Di Domenico, M.; Castoria, G.; de Falco, A.; Bontempo, P.; Nola, E.; Auricchio, F. Tyrosine kinase/p21ras/MAPkinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 1996, 15, 1292-1300.
51. Chen, Z.; Yuhanna, I. S.; Galcheva-Gargova, Z.; Karas, R. H.; Mendelsohn, M. E.; Shaul, P. W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 1999, 103, 401-406.
52. Jessop, H. L.; Sjoberg, M.; Cheng, M. Z.; Zaman, G.; Wheeler-Jones, C. P.; Lanyon, L. E. Mechanical strain and estrogen activate estrogen receptor alpha in bone cells. J. Bone Miner. Res. 2001, 16, 1045-1055.
53. Castoria, G.; Migliaccio, A.; Bilancio, A.; Di Domenico, M.; de Falco, A.; Lombardi, M.; Fiorentino, R.; Varricchio, L.; Barone, M. V.; Auricchio, F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 2001, 20, 6050-6059.
54. Lewis, J. S.; Thomas, T. J.; Pestell, R. G.; Albanese, C.; Gallo, M. A.; Thomas, T. Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells. J. Mol. Endocrinol. 2005, 34, 91-105.
55. Maggiolini, M.; Vivacqua, A.; Fasanella, G.; Recchia, A. G.; Sisci, D.; Pezzi, V.; Montanaro, D.; Musti, A. M.; Picard, D.; Ando, S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 2004, 279, 27008-27016.
56. Razandi, M.; Pedram, A.; Greene, G. L.; Levin, E. R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 1999, 13, 307-319.
57. Morelli, C.; Garofalo, C.; Bartucci, M.; Surmacz, E. Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells. Oncogene 2003, 22, 4007-4016.
58. Toran-Allerand, C. D.; Guan, X.; MacLusky, N. J.; Horvath, T. L.; Diano, S.; Singh, M.; Connolly, E. S., Jr.; Nethrapalli, I. S.; Tinnikov, A. A. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J. Neurosci. 2002, 22, 8391-8401.
59. Pappas, T. C.; Gametchu, B.; Watson, C. S. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J. 1995, 9, 404-410.
60. Watson, C. S.; Norfleet, A. M.; Pappas, T. C.; Gametchu, B. Rapid actions of estrogens in GH3/B6 pituitary tumor cells via a plasma membrane version of estrogen receptor-alpha. Steroids 1999, 64, 5-13.
61. Razandi, M.; Pedram, A.; Merchenthaler, I.; Greene, G. L.; Levin, E. R. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 2004, 18, 2854-2865.
62. Kousteni, S.; Bellido, T.; Plotkin, L. I.; O'Brien, C. A.; Bodenner, D. L.; Han, L.; Han, K.; DiGregorio, G. B.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Roberson, P. K.; Weinstein, R. S.; Jilka, R. L.; Manolagas, S. C. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001, 104, 719-730.
63. Chambliss, K. L.; Simon, L.; Yuhanna, I. S.; Mineo, C.; Shaul, P. W. Dissecting the basis of nongenomic activation of endothelial nitric oxide synthase by estradiol: role of ERalpha domains with known nuclear functions. Mol. Endocrinol. 2005, 19, 277-289.
64. Razandi, M.; Oh, P.; Pedram, A.; Schnitzer, J.; Levin, E. R. ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol. Endocrinol. 2002, 16, 100-115.
65. Anderson, R. G. The caveolae membrane system. Annu. Rev. Biochem. 1998, 67, 199-225.
66. Acconcia, F.; Ascenzi, P.; Bocedi, A.; Spisni, E.; Tomasi, V.; Trentalance, A.; Visca, P.; Marino, M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol. Biol. Cell 2005, 16, 231-237.
67. Marino, M.; Ascenzi, P. Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation. Steroids 2008, 73(9-10), 853-858.
68. Pelicci, G.; Dente, L.; De Giuseppe, A.; Verducci-Galletti, B.; Giuli, S.; Mele, S.; Vetriani, C.; Giorgio, M.; Pandolfi, P. P.; Cesareni, G.; Pelicci, P. G. A family of Shc related proteins with conserved PTB, CH1 and SH2 regions. Oncogene 1996, 13, 633-641.
69. Song, R. X.; Barnes, C. J.; Zhang, Z.; Bao, Y.; Kumar, R.; Santen, R. J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. USA 2004, 101, 2076-2081.
70. Wong, C. W.; McNally, C.; Nickbarg, E.; Komm, B. S.; Cheskis, B. J. Estrogen receptor-interacting protein that modulates its non-genomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl. Acad. Sci. USA 2002, 99, 14783-14788.
71. Greger, J. G.; Guo, Y.; Henderson, R.; Ross, J. F.; Cheskis, B. J. Characterization of MNAR expression. Steroids 2006, 71, 317-322.
72. Vadlamudi, R. K.; Wang, R. A.; Mazumdar, A.; Kim, Y.; Shin, J.; Sahin, A.; Kumar, R. Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha. J. Biol. Chem. 2001, 276, 38272-38279.
73. Vadlamudi, R. K.; Manavathi, B.; Balasenthil, S.; Nair, S. S.; Yang, Z.; Sahin, A. A.; Kumar, R. Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res. 2005, 65, 7724-7732.
74. Rajhans, R.; Nair, H. B.; Nair, S. S.; Cortez, V.; Ikuko, K.; Kirma, N. B.; Zhou, D.; Holden, A. E.; Brann, D. W.; Chen, S.; Tekmal, R. R.; Vadlamudi, R. K. Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol. Endocrinol. 2008, 22, 649-664.
75. Catalano, S.; Marsico, S.; Giordano, C.; Mauro, L.; Rizza, P.; Panno, M. L.; Ando, S. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J. Biol. Chem. 2003, 278, 28668-28676.
76. Vadlamudi, R. K.; Kumar, R. Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl. Recept. Signal. 2007, 5, e004.
77. Barletta, F.; Wong, C. W.; McNally, C.; Komm, B. S.; Katzenellenbogen, B.; Cheskis, B. J. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol. Endocrinol. 2004, 18, 1096-1108.
78. Greger, J. G.; Fursov, N.; Cooch, N.; McLarney, S.; Freedman, L. P.; Edwards, D. P.; Cheskis, B. J. Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol. Cell Biol. 2007, 27, 1904-1913.
79. Cheskis, B. J.; Greger, J.; Cooch, N.; McNally, C.; McLarney, S.; Lam, H. S.; Rutledge, S.; Mekonnen, B.; Hauze, D.; Nagpal, S.; Freedman, L. P. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 2008, 73, 901-905.
80. Watters, J. J.; Campbell, J. S.; Cunningham, M. J.; Krebs, E. G.; Dorsa, D. M. Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology 1997, 138, 4030-4033.
81. Migliaccio, A.; Castoria, G.; Di Domenico, M.; De Falco, A.; Bilancio, A.; Auricchio, F. Src is an initial target of sex steroid hormone action. Ann. N. Y. Acad. Sci. 2002, 963, 185-190.
82. Arold, S. T.; Ulmer, T. S.; Mulhern, T. D.; Werner, J. M.; Ladbury, J. E.; Campbell, I. D.; Noble, M. E. The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases. J. Biol. Chem. 2001, 276, 17199-17205.
83. Duan, R.; Xie, W.; Burghardt, R. C.; Safe, S. Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. J. Biol. Chem. 2001, 276, 11590-11598.
84. Duan, R.; Xie, W.; Li, X.; McDougal, A.; Safe, S. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2002, 294, 384-394.
85. O'Malley, B. W. A life-long search for the molecular pathways of steroid hormone action. Mol. Endocrinol. 2005, 19, 1402-1411.
86. Font de Mora, J.; Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell Biol. 2000, 20, 5041-5047.
87. Taniguchi, C. M.; Emanuelli, B.; Kahn, C. R. Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell. Biol. 2006, 7, 85-96.
88. Salzman, A.; Wan, C. F.; Rubin, C. S. Biogenesis, transit, and functional properties of the insulin proreceptor and modified insulin receptors in 3T3-L1 adipocytes. Use of monensin to probe proreceptor cleavage and generate altered receptor subunits. Biochemistry 1984, 23, 6555-6565.
89. Robertson, J. F.; Nicholson, R. I.; Bundred, N. J.; Anderson, E.; Rayter, Z.; Dowsett, M.; Fox, J. N.; Gee, J. M.; Webster, A.; Wakeling, A. E.; Morris, C.; Dixon, M. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17betadiol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res. 2001, 61, 6739-6746.
90. Jacobs, S.; Kull, F. C., Jr.; Cuatrecasas, P. Monensin blocks the maturation of receptors for insulin and somatomedin C: identification of receptor precursors. Proc. Natl. Acad. Sci. USA 1983, 80, 1228-1231.
91. Slaaby, R.; Schaffer, L.; Lautrup-Larsen, I.; Andersen, A. S.; Shaw, A. C.; Mathiasen, I. S.; Brandt, J. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J. Biol. Chem. 2006, 281, 25869-25874.
92. Benyoucef, S.; Surinya, K. H.; Hadaschik, D.; Siddle, K. Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation. Biochem. J. 2007, 403, 603-613.
93. Avruch, J. Insulin signal transduction through protein kinase cascades. Mol. Cell Biochem. 1998, 182, 31-48.
94. Cai, D.; Dhe-Paganon, S.; Melendez, P. A.; Lee, J.; Shoelson, S. E. Two new substrates in insulin signaling, IRS5/DOK4 and IRS6/DOK5. J. Biol. Chem. 2003, 278, 25323-25330.
95. Sun, X. J.; Rothenberg, P.; Kahn, C. R.; Backer, J. M.; Araki, E.; Wilden, P. A.; Cahill, D. A.; Goldstein, B. J.; White, M. F. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 1991, 352, 73-77.
96. Sun, X. J.; Wang, L. M.; Zhang, Y.; Yenush, L.; Myers, M. G., Jr.; Glasheen, E.; Lane, W. S.; Pierce, J. H.; White, M. F. Role of IRS-2 in insulin and cytokine signalling. Nature 1995, 377, 173-177.
97. Lavan, B. E.; Fantin, V. R.; Chang, E. T.; Lane, W. S.; Keller, S. R.; Lienhard, G. E. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J. Biol. Chem. 1997, 272, 21403-21407.
98. Fantin, V. R.; Sparling, J. D.; Slot, J. W.; Keller, S. R.; Lienhard, G. E.; Lavan, B. E. Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells. J. Biol. Chem. 1998, 273, 10726-10732.
99. Virkamaki, A.; Ueki, K.; Kahn, C. R. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J. Clin. Invest. 1999, 103, 931-943.
100. Myers, M. G., Jr.; Mendez, R.; Shi, P.; Pierce, J. H.; Rhoads, R.; White, M. F. The COOH-terminal tyrosine phosphorylation sites on IRS-1 bind SHP-2 and negatively regulate insulin signaling. J. Biol. Chem. 1998, 273, 26908-26914.
101. Kahn, C. R.; White, M. F. The insulin receptor and the molecular mechanism of insulin action. J. Clin. Invest. 1988, 82, 1151-1156.
102. Cheatham, B.; Vlahos, C. J.; Cheatham, L.; Wang, L.; Blenis, J.; Kahn, C. R. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell Biol. 1994, 14, 4902-4911.
103. Ouwens, D. M.; van der Zon, G. C.; Pronk, G. J.; Bos, J. L.; Moller, W.; Cheatham, B.; Kahn, C. R.; Maassen, J. A. A mutant insulin receptor induces formation of a Shc-growth factor receptor bound protein 2 (Grb2) complex and p21ras-GTP without detectable interaction of insulin receptor substrate 1 (IRS1) with Grb2. Evidence for IRS1-independent p21ras-GTP formation. J. Biol. Chem. 1994, 269, 33116-33122.
104. Amoui, M.; Craddock, B. P.; Miller, W. T. Differential phosphorylation of IRS-1 by insulin and insulin-like growth factor I receptors in Chinese hamster ovary cells. J. Endocrinol. 2001, 171, 153-162.
105. Froesch, E. R.; Schmid, C.; Schwander, J.; Zapf, J. Actions of insulin-like growth factors. Annu. Rev. Physiol. 1985, 47, 443-467.
106. Surmacz, E. Function of the IGF-I receptor in breast cancer. J. Mammary Gland Biol. Neoplasia 2000, 5, 95-105.
107. Yee, D. The insulin-like growth factor system as a treatment target in breast cancer. Semin. Oncol. 2002, 29, 86-95.
108. Gross, J. M.; Yee, D. The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Rev. 2003, 22, 327-336.
109. Baserga, R. The IGF-I receptor in cancer research. Exp. Cell Res. 1999, 253, 1-6.
110. Baserga, R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000, 19, 5574-5581.
111. Cullen, K. J.; Yee, D.; Sly, W. S.; Perdue, J.; Hampton, B.; Lippman, M. E.; Rosen, N. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res. 1990, 50, 48-53.
112. Pezzino, V.; Papa, V.; Milazzo, G.; Gliozzo, B.; Russo, P.; Scalia, P. L. Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann. N. Y. Acad. Sci. 1996, 784, 189-201.
113. Turner, B. C.; Haffty, B. G.; Narayanan, L.; Yuan, J.; Havre, P. A.; Gumbs, A. A.; Kaplan, L.; Burgaud, J. L.; Carter, D.; Baserga, R.; Glazer, P. M. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res. 1997, 57, 3079-3083.
114. Resnik, J. L.; Reichart, D. B.; Huey, K.; Webster, N. J.; Seely, B. L. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res. 1998, 58, 1159-1164.
115. DeChiara, T. M.; Efstratiadis, A.; Robertson, E. J. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 1990, 345, 78-80.
116. Hankinson, S. E.; Willett, W. C.; Colditz, G. A.; Hunter, D. J.; Michaud, D. S.; Deroo, B.; Rosner, B.; Speizer, F. E.; Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351, 1393-1396.
117. Gebauer, G.; Jager, W.; Lang, N. mRNA expression of components of the insulin-like growth factor system in breast cancer cell lines, tissues, and metastatic breast cancer cells. Anticancer Res. 1998, 18, 1191-1195.
118. Yee, D.; Cullen, K. J.; Paik, S.; Perdue, J. F.; Hampton, B.; Schwartz, A.; Lippman, M. E.; Rosen, N. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res. 1988, 48, 6691-6696.
119. Rocha, R. L.; Hilsenbeck, S. G.; Jackson, J. G.; VanDenBerg, C. L.; Weng, C.; Lee, A. V.; Yee, D. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin. Cancer Res. 1997, 3, 103-109.
120. Lee, A. V.; Jackson, J. G.; Gooch, J. L.; Hilsenbeck, S. G.; Coronado-Heinsohn, E.; Osborne, C. K.; Yee, D. Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol. Endocrinol. 1999, 13, 787-796.
121. Dunn, S. E.; Hardman, R. A.; Kari, F. W.; Barrett, J. C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997, 57, 2687-2693.
122. Nolan, M. K.; Jankowska, L.; Prisco, M.; Xu, S.; Guvakova, M. A.; Surmacz, E. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells. Int. J. Cancer 1997, 72, 828-834.
123. Guvakova, M. A.; Surmacz, E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res. 1997, 57, 2606-2610.
124. Salerno, M.; Sisci, D.; Mauro, L.; Guvakova, M. A.; Ando, S.; Surmacz, E. Insulin receptor substrate 1 is a target for the pure antiestrogen ICI 182,780 in breast cancer cells. Int. J. Cancer 1999, 81, 299-304.
125. Ho, G. H.; Ji, C. Y.; Phang, B. H.; Lee, K. O.; Soo, K. C.; Ng, E. H. Tamoxifen alters levels of serum insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: a prospective paired cohort study. Ann. Surg. Oncol. 1998, 5, 361-367.
126. Koda, M.; Sulkowski, S.; Garofalo, C.; Kanczuga-Koda, L.; Sulkowska, M.; Surmacz, E. Expression of the insulin-like growth factor-I receptor in primary breast cancer and lymph node metastases: correlations with estrogen receptors alpha and beta. Horm. Metab. Res. 2003, 35, 794-801.
127. Railo, M. J.; von Smitten, K.; Pekonen, F. The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur. J. Cancer 1994, 30A, 307-311.
128. Mauro, L.; Salerno, M.; Morelli, C.; Boterberg, T.; Bracke, M. E.; Surmacz, E. Role of the IGF-I receptor in the regulation of cell-cell adhesion: implications in cancer development and progression. J. Cell Physiol. 2003, 194, 108-116.
129. Jerome, L.; Shiry, L.; Leyland-Jones, B. Anti-insulin-like growth factor strategies in breast cancer. Semin. Oncol. 2004, 31, 54-63.
130. Karey, K. P.; Sirbasku, D. A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17 beta-estradiol. Cancer Res. 1988, 48, 4083-4092.
131. Sisci, D.; Surmacz, E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Curr. Pharm. Des. 2007, 13, 705-717.
132. Mauro, L.; Salerno, M.; Panno, M. L.; Bellizzi, D.; Sisci, D.; Miglietta, A.; Surmacz, E.; Ando, S. Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells. Biochem. Biophys. Res. Commun. 2001, 288, 685-689.
133. Stewart, A. J.; Johnson, M. D.; May, F. E.; Westley, B. R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 1990, 265, 21172-21178.
134. Thorsen, T.; Lahooti, H.; Rasmussen, M.; Aakvaag, A. Oestradiol treatment increases the sensitivity of MCF-7 cells for the growth stimulatory effect of IGF-I. J. Steroid Biochem. Mol. Biol. 1992, 41, 537-540.
135. Wiseman, L. R.; Johnson, M. D.; Wakeling, A. E.; Lykkesfeldt, A. E.; May, F. E.; Westley, B. R. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur. J. Cancer 1993, 29A, 2256-2264.
136. Varma, H.; Conrad, S. E. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling. Cancer Res. 2002, 62, 3985-3991.
137. Yang, X. F.; Beamer, W. G.; Huynh, H.; Pollak, M. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. Cancer Res. 1996, 56, 1509-1511.
138. Jones, J. I.; Clemmons, D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16, 3-34.
139. Clemmons, D. R.; Camacho-Hubner, C.; Coronado, E.; Osborne, C. K. Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology 1990, 127, 2679-2686.
140. Yee, D.; Favoni, R. E.; Lippman, M. E.; Powell, D. R. Identification of insulin-like growth factor binding proteins in breast cancer cells. Breast Cancer Res. Treat. 1991, 18, 3-10.
141. Winston, R.; Kao, P. C.; Kiang, D. T. Regulation of insulin-like growth factors by antiestrogen. Breast Cancer Res. Treat. 1994, 31, 107-115.
142. Parisot, J. P.; Leeding, K. S.; Hu, X. F.; DeLuise, M.; Zalcberg, J. R.; Bach, L. A. Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. Breast Cancer Res. Treat. 1999, 55, 231-242.
143. Gucev, Z. S.; Oh, Y.; Kelley, K. M.; Rosenfeld, R. G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996, 56, 1545-1550.
144. Pratt, S. E.; Pollak, M. N. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem. Biophys. Res. Commun. 1994, 198, 292-297.
145. Lange, C. A. Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol. Endocrinol. 2004, 18, 269-278.
146. Nordeen, S. K.; Moyer, M. L.; Bona, B. J. The coupling of multiple signal transduction pathways with steroid response mechanisms. Endocrinology 1994, 134, 1723-1732.
147. Weigel, N. L.; Zhang, Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 1998, 76, 469-479.
148. Lannigan, D. A. Estrogen receptor phosphorylation. Steroids 2003, 68, 1-9.
149. Sun, M.; Paciga, J. E.; Feldman, R. I.; Yuan, Z.; Coppola, D.; Lu, Y. Y.; Shelley, S. A.; Nicosia, S. V.; Cheng, J. Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 2001, 61, 5985-5991.
150. Kahlert, S.; Nuedling, S.; van Eickels, M.; Vetter, H.; Meyer, R.; Grohe, C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 2000, 275, 18447-18453.
151. Zhang, Z.; Kumar, R.; Santen, R. J.; Song, R. X. The role of adapter protein Shc in estrogen non-genomic action. Steroids 2004, 69, 523-529.
152. Song, R. X.; McPherson, R. A.; Adam, L.; Bao, Y.; Shupnik, M.; Kumar, R.; Santen, R. J. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol. Endocrinol. 2002, 16, 116-127.
153. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26, 6469-6487.
154. Denger, S.; Bahr-Ivacevic, T.; Brand, H.; Reid, G.; Blake, J.; Seifert, M.; Lin, C. Y.; May, K.; Benes, V.; Liu, E. T.; Gannon, F. Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast-specific regulation of the insulin-like growth factor binding protein 4 gene. Mol. Endocrinol. 2008, 22, 361-379.
155. Burgess, A. W.; Cho, H. S.; Eigenbrot, C.; Ferguson, K. M.; Garrett, T. P.; Leahy, D. J.; Lemmon, M. A.; Sliwkowski, M. X.; Ward, C. W.; Yokoyama, S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003, 12, 541-552.
156. Davidson, N. E.; Gelmann, E. P.; Lippman, M. E.; Dickson, R. B. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol. Endocrinol. 1987, 1, 216-223.
157. deFazio, A.; Chiew, Y. E.; McEvoy, M.; Watts, C. K.; Sutherland, R. L. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ. 1997, 8, 903-911.
158. Sharma, A. K.; Grimshaw, D.; Horgan, K.; Douglas-Jones, A.; Mansel, R.; Geet, J.; Nicholson, R. Investigation of the mechanisms determining the inverse relationship between oestrogen and epidermal growth factor receptors in primary human breast cancer. Breast 1997, 6, 371-378.
159. Levin, E. R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 2003, 17, 309-317.
160. Brooks-Asplund, E. M.; Shoukas, A. A.; Kim, S. Y.; Burke, S. A.; Berkowitz, D. E. Estrogen has opposing effects on vascular reactivity in obese, insulin-resistant male Zucker rats. J. Appl. Physiol. 2002, 92, 2035-2044.
161. Dickson, R. B.; Huff, K. K.; Spencer, E. M.; Lippman, M. E. Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. Endocrinology 1986, 118, 138-142.
162. Ignar-Trowbridge, D. M.; Nelson, K. G.; Bidwell, M. C.; Curtis, S. W.; Washburn, T. F.; McLachlan, J. A.; Korach, K. S. Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. USA 1992, 89, 4658-4662.
163. Kato, S.; Endoh, H.; Masuhiro, Y.; Kitamoto, T.; Uchiyama, S.; Sasaki, H.; Masushige, S.; Gotoh, Y.; Nishida, E.; Kawashima, H.; et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270, 1491-1494.
164. Bunone, G.; Briand, P. A.; Miksicek, R. J.; Picard, D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 1996, 15, 2174-2183.
165. Razandi, M.; Pedram, A.; Park, S. T.; Levin, E. R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 2003, 278, 2701-2712.
166. Panno, M. L.; Mauro, L.; Marsico, S.; Bellizzi, D.; Rizza, P.; Morelli, C.; Salerno, M.; Giordano, F.; Ando, S. Evidence that the mouse insulin receptor substrate-1 belongs to the gene family on which the promoter is activated by estrogen receptor alpha through its interaction with Sp1. J. Mol. Endocrinol. 2006, 36, 91-105.
167. Dufourny, B.; Alblas, J.; van Teeffelen, H. A.; van Schaik, F. M.; van der Burg, B.; Steenbergh, P. H.; Sussenbach, J. S. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J. Biol. Chem. 1997, 272, 31163-31171.
168. Morelli, C.; Garofalo, C.; Sisci, D.; del Rincon, S.; Cascio, S.; Tu, X.; Vecchione, A.; Sauter, E. R.; Miller, W. H., Jr.; Surmacz, E. Nuclear insulin receptor substrate 1 interacts with estrogen receptor alpha at ERE promoters. Oncogene 2004, 23, 7517-7526.
169. Lassak, A.; Del Valle, L.; Peruzzi, F.; Wang, J. Y.; Enam, S.; Croul, S.; Khalili, K.; Reiss, K. Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen. J. Biol. Chem. 2002, 277, 17231-17238.
170. Tu, X.; Batta, P.; Innocent, N.; Prisco, M.; Casaburi, I.; Belletti, B.; Baserga, R. Nuclear translocation of insulin receptor substrate-1 by oncogenes and Igf-I. Effect on ribosomal RNA synthesis. J. Biol. Chem. 2002, 277, 44357-44365.
171. Lanzino, M.; Garofalo, C.; Morelli, C.; Le Pera, M.; Casaburi, I.; McPhaul, M. J.; Surmacz, E.; Ando, S.; Sisci, D. Insulin receptor substrate 1 modulates the transcriptional activity and the stability of androgen receptor in breast cancer cells. Breast Cancer Res. Treat. 2008.
172. Sisci, D.; Morelli, C.; Cascio, S.; Lanzino, M.; Garofalo, C.; Reiss, K.; Garcia, M.; Russo, A.; Ando, S.; Surmacz, E. The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships. Ann. Oncol. 2007, 18(Suppl 6), vi81-85.
173. Ravichandran, K. S. Signaling via Shc family adapter proteins. Oncogene 2001, 20, 6322-6330.
174. Altschuler, D.; Yamamoto, K.; Lapetina, E. G. Insulin-like growth factor-1-mediated association of p85 phosphatidylinositol 3-kinase with pp 185: requirement of SH2 domains for in vivo interaction. Mol. Endocrinol. 1994, 8, 1139-1146.
175. Yamamoto, K.; Altschuler, D.; Wood, E.; Horlick, K.; Jacobs, S.; Lapetina, E. G. Association of phosphorylated insulin-like growth factor-I receptor with the SH2 domains of phosphatidylinositol 3-kinase p85. J. Biol. Chem. 1992, 267, 11337-11343.
176. Vanhaesebroeck, B.; Waterfield, M. D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 1999, 253, 239-254.
177. Simoncini, T.; Hafezi-Moghadam, A.; Brazil, D. P.; Ley, K.; Chin, W. W.; Liao, J. K. Interaction of oestrogen receptor with the regu latory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407, 538-541.
178. Lee, Y. R.; Park, J.; Yu, H. N.; Kim, J. S.; Youn, H. J.; Jung, S. H. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem. Biophys. Res. Commun. 2005, 336, 1221-1226.
179. Ahmad, S.; Singh, N.; Glazer, R. I. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem. Pharmacol. 1999, 58, 425-430.
180. Campbell, R. A.; Bhat-Nakshatri, P.; Patel, N. M.; Constantinidou, D.; Ali, S.; Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 2001, 276, 9817-9824.
181. Clark, D. E.; Poteet-Smith, C. E.; Smith, J. A.; Lannigan, D. A. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J. 2001, 20, 3484-3494.
182. Stoica, A.; Saceda, M.; Fakhro, A.; Joyner, M.; Martin, M. B. Role of insulin-like growth factor-I in regulating estrogen receptor-alpha gene expression. J. Cell Biochem. 2000, 76, 605-614.
183. Martin, M. B.; Franke, T. F.; Stoica, G. E.; Chambon, P.; Katzenellenbogen, B. S.; Stoica, B. A.; McLemore, M. S.; Olivo, S. E.; Stoica, A. A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I. Endocrinology 2000, 141, 4503-4511.
184. Faridi, J.; Wang, L.; Endemann, G.; Roth, R. A. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin. Cancer Res. 2003, 9, 2933-2939.
185. Liu, W.; Bagaitkar, J.; Watabe, K. Roles of AKT signal in breast cancer. Front. Biosci. 2007, 12, 4011-4019.
186. Fernando, R. I.; Wimalasena, J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol. Biol. Cell 2004, 15, 3266-3284.
187. Li, Y.; Liu, J.; Liu, X.; Xing, K.; Wang, Y.; Li, F.; Yao, L. Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl. Biochem. Biotechnol. 2006, 135, 181-192.
188. Biggs, W. H., 3rd; Meisenhelder, J.; Hunter, T.; Cavenee, W. K.; Arden, K. C. Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc. Natl. Acad. Sci. USA 1999, 96, 7421-7426.
189. Moelling, K.; Schad, K.; Bosse, M.; Zimmermann, S.; Schweneker, M. Regulation of Raf-Akt Cross-talk. J. Biol. Chem. 2002, 277, 31099-31106.
190. Sells, M. A.; Chernoff, J. Emerging from the Pak: the p21-activated protein kinase family. Trends Cell Biol. 1997, 7, 162-167.
191. Edwards, D. P.; Weigel, N. L.; Nordeen, S. K.; Beck, C. A. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res. Treat. 1993, 27, 41-56.
192. Endoh, H.; Maruyama, K.; Masuhiro, Y.; Kobayashi, Y.; Goto, M.; Tai, H.; Yanagisawa, J.; Metzger, D.; Hashimoto, S.; Kato, S. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor alpha. Mol. Cell Biol. 1999, 19, 5363-5372.
193. Frodin, M.; Gammeltoft, S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell Endocrinol. 1999, 151, 65-77.
194. Joel, P. B.; Smith, J.; Sturgill, T. W.; Fisher, T. L.; Blenis, J.; Lannigan, D. A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell Biol. 1998, 18, 1978-1984.
195. Jiang, G.; Zhang, B. B. Modulation of insulin signalling by insulin sensitizers. Biochem. Soc. Trans. 2005, 33, 358-361.
196. Mawson, A.; Lai, A.; Carroll, J. S.; Sergio, C. M.; Mitchell, C. J.; Sarcevic, B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol. Cell Endocrinol. 2005, 229, 161-173.
197. Song, R. X.; Zhang, Z.; Chen, Y.; Bao, Y.; Santen, R. J. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 2007, 148, 4091-4101.
198. Tremblay, A.; Tremblay, G. B.; Labrie, F.; Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol. Cell 1999, 3, 513-519.
199. Gonzalez, F. A.; Raden, D. L.; Davis, R. J. Identification of substrate recognition determinants for human ERK1 and ERK2 protein kinases. J. Biol. Chem. 1991, 266, 22159-22163.